| HIV Infection |
1 |
1 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.98 |
| Patient Safety |
0 |
0.89 |
| Brachial |
0 |
0.79 |
| Lipids Management |
0 |
0.56 |
| Arthralgia |
0 |
0.38 |
| Adverse Effects |
0 |
0.32 |
| Pain |
0 |
0.32 |
| Pain Management |
0 |
0.28 |
| Vitamin D Deficiency |
0 |
0.22 |
| Headache |
0 |
0.21 |
| Emesis |
0 |
0.16 |
| Nausea |
0 |
0.16 |
| Sinus |
0 |
0.16 |
| Vitamin |
0 |
0.16 |
| Diarrhea |
0 |
0.14 |
| AIDS |
0 |
0.08 |
| Anxiety |
0 |
0.08 |
| Food and Drug Administration (FDA) |
0 |
0.08 |
| Grant |
0 |
0.08 |
| Metabolism |
0 |
0.08 |
| NHS |
0 |
0.08 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.08 |
| Outpatient Clinic |
0 |
0.08 |
| Primary Care |
0 |
0.08 |
| Sexual Health |
0 |
0.08 |
| Triglycerides |
0 |
0.08 |
| Viral Load |
0 |
0.08 |
| Anxiety Disorder |
0 |
0.07 |
| Health Care Reform |
0 |
0.07 |